Pharmaceuticals & Therapeutics

A quiet revolution is underway in animal feed, with enzymes driving a $4.6B market. This isn't just about cost; it's a tech-fueled shift to profitability.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

A silent health crisis affecting a billion women is becoming a major economic focus. One firm's move to train a new workforce signals a paradigm shift.

The K-beauty giant's massive Amazon sale is more than just discounts; it's a strategic play to launch products, capture new markets, and solidify its e-commerce dominance.

With $4.6M in funding, a San Diego startup is challenging the multi-million dollar surgical robotics market with a handheld, AI-powered device.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

The appointment of Bethany Sensenig, a veteran of PE-backed turnarounds, signals CenExel is preparing for a major push to dominate the clinical research market.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

With Hillary Aiken leading its new philanthropic arm, 23andMe Research Institute bets on private giving to accelerate its 'public good' DNA revolution.

DEWAR'S new U.S. Open whisky isn't just a spirit; it's a story of place, blending Scottish heritage with Long Island wine casks from Wölffer Estate.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

Goldfish Swim School's new 'Dads & Minis' program is more than a swim class; it's a strategic move to engage fathers, combat drowning stats, and innovate.

Companies like eGenesis are turning science fiction into reality with gene-edited pig organs. This is the story of a medical revolution at a crossroads.

New detachable sensor leads from Monnit allow for instant recertification, eliminating costly downtime in pharma and healthcare while ensuring data integrity.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

RedHill Biopharma's new financing provides crucial cash, but the real story is in the warrants and the hunt for a strategic acquisition. A deep dive.

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?